☰

James Patrick Allison - Publications

Affiliations: 
1985-1997 Molecular and Cell Biology University of California, Berkeley, Berkeley, CA, United States 
 1997-2004 Rheumatology University of California, San Francisco, San Francisco, CA 
 2004-2012 Weill Cornell Medical College, New York, NY, United States 
 2006-2012 Memorial Sloan-Kettering Cancer Center, Rockville Centre, NY, United States 
 2012- Immunology M. D. Anderson Cancer Center, Houston, TX, United States 
Area:
Immunotherapy
Website:
https://faculty.mdanderson.org/profiles/james_allison.html
Tree Info Similar researchers PubMed Report error

378 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, Hanna A, Zhang S, Amancherla K, Tai W, Wright JJ, ... ... Allison JP, et al. T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature. PMID 36385524 DOI: 10.1038/s41586-022-05432-3  0.421
2022 Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, ... ... Allison JP, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 40: 509-523.e6. PMID 35537412 DOI: 10.1016/j.ccell.2022.04.004  0.374
2021 Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, ... ... Allison JP, et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nature Communications. 12: 6071. PMID 34663807 DOI: 10.1038/s41467-021-26282-z  0.388
2021 Sharma N, Atolagbe OT, Ge Z, Allison JP. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. The Journal of Experimental Medicine. 218. PMID 33974041 DOI: 10.1084/jem.20201811  0.407
2020 Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, et al. mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Science Translational Medicine. 12. PMID 32554706 DOI: 10.1126/Scitranslmed.Abc4220  0.363
2020 Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, ... ... Allison JP, et al. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nature Communications. 11: 1839. PMID 32296058 DOI: 10.1038/S41467-020-15538-9  0.436
2020 Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, ... ... Allison JP, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Science Translational Medicine. 12. PMID 32238575 DOI: 10.1126/Scitranslmed.Aaz3577  0.486
2020 Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, ... ... Allison JP, et al. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications. 11: 603. PMID 32001676 DOI: 10.1038/S41467-019-14273-0  0.497
2020 Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, ... ... Allison J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. PMID 31942075 DOI: 10.1038/S41586-019-1922-8  0.414
2020 Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nature Reviews. Immunology. PMID 31925406 DOI: 10.1038/S41577-020-0275-8  0.46
2020 Mok S, Chin R, Allison JP. Abstract LB-399: Late interferon-gamma blockade improves antitumor efficacy of anti-CTLA-4 and anti-PD-1 combination treatment Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Lb-399  0.386
2019 Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, ... ... Allison JP, et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nature Medicine. PMID 31873309 DOI: 10.1038/S41591-019-0694-X  0.442
2019 Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, Wang J, Blando J, Byers LA, Yanamandra N, Brett S, Morley P, Sharma P, Allison J, Wistuba II, et al. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. Journal For Immunotherapy of Cancer. 7: 351. PMID 31843013 DOI: 10.1186/S40425-019-0827-2  0.388
2019 de Groot J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, Pei B, O'brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, ... ... Allison J, et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro-Oncology. PMID 31755915 DOI: 10.1093/Neuonc/Noz185  0.343
2019 Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, Cogdill AP, Mancuso JJ, Wargo JA, Pe'er D, Allison JP. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings of the National Academy of Sciences of the United States of America. PMID 31636208 DOI: 10.1073/Pnas.1821218116  0.467
2019 Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. PMID 31611368 DOI: 10.1073/Pnas.1908079116  0.333
2019 Saha A, Taylor PA, Lees CJ, Panoskaltsis-Mortari A, Osborn MJ, Feser CJ, Thangavelu G, Melchinger W, Refaeli Y, Hill GR, Munn DH, Murphy WJ, Serody JS, Maillard I, Kreymborg K, ... ... Allison JP, et al. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. Jci Insight. 4. PMID 31578305 DOI: 10.1172/Jci.Insight.127716  0.369
2019 Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P. Blockade of CTLA-4 and PD-1 Enhances adoptive T-cell therapy efficacy in an ICOS mediated manner. Cancer Immunology Research. PMID 31466995 DOI: 10.1158/2326-6066.Cir-18-0873  0.541
2019 Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Chaparro-Riggers J, Subudhi SK, Borin Scutti J, Higa MG, Zhao H, Yadav SS, ... ... Allison JP, et al. Characterization and comparison of GITR expression in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31358539 DOI: 10.1158/1078-0432.Ccr-19-0289  0.4
2019 Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Carmagnani Pestana R, Vauthey JN, Allison JP, Sharma P. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunology Research. PMID 31289040 DOI: 10.1158/2326-6066.Cir-18-0605  0.343
2019 Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 3469-3470. PMID 31160495 DOI: 10.1158/1078-0432.CCR-19-0402  0.375
2019 Sharma N, Vacher J, Allison JP. TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. Proceedings of the National Academy of Sciences of the United States of America. PMID 31076558 DOI: 10.1073/Pnas.1819004116  0.47
2019 Wei SC, Sharma R, Anang NAS, Levine JH, Zhao Y, Mancuso JJ, Setty M, Sharma P, Wang J, Pe'er D, Allison JP. Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity. PMID 30926234 DOI: 10.1016/J.Immuni.2019.03.004  0.494
2019 Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, ... ... Allison JP, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30635425 DOI: 10.1073/Pnas.1811067116  0.479
2019 Nusrat M, Roszik J, Katkhuda R, Menter D, Raghav KPS, Morris VK, Sharma P, Allison JP, Blando JM, Maru DM, Lizee G, Janku F, Overman MJ, Kopetz S. Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts). Journal of Clinical Oncology. 37: 3604-3604. DOI: 10.1200/Jco.2019.37.15_Suppl.3604  0.389
2019 Mok S, Duffy CR, Anang NAS, Allison JP. Abstract A205: Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A205  0.443
2019 Mitra A, Andrews MC, Roh W, Macedo MPd, Reuben A, Carapeto F, Wang F, Reddy SM, Wani K, Spencer C, Miller J, Schalck A, Little LD, Sakellariou-Thompson DA, Gumbs C, ... ... Allison JP, et al. Abstract 3776: Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy Cancer Research. 79: 3776-3776. DOI: 10.1158/1538-7445.Sabcs18-3776  0.453
2019 Gopalakrishnan V, Andrews M, Chen W, Spencer C, Vence L, Reuben A, Cooper ZA, Prieto PA, Tetzlaff MT, Khan MAW, Lazar A, Hudgens CW, Haydu LE, Tawbi HA, Hwu P, ... ... Allison JP, et al. Abstract 1493: Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome Immunology. DOI: 10.1158/1538-7445.Sabcs18-1493  0.325
2019 Helmink BA, Reddy S, Blando J, Liang Y, Warren S, Gopalakrishnan V, Tawbi HA, Amaria RN, Davies M, Gershenwald JE, Burton E, Basar R, Lazar AJ, Hudgens CW, Rezvani K, ... Allison JP, et al. Abstract 499: NanoString®GeoMx®digital spatial profiling further defines the role of B cells in the response to immune checkpoint blockade Cancer Research. 79: 499-499. DOI: 10.1158/1538-7445.Am2019-499  0.497
2019 Reddy SM, Helmink B, Gao J, Zhang S, Yizhak K, Sade-Feldman M, Basar R, Blando J, Han G, Gopalakrishnan V, Zhao H, Liu W, Tawbi H, Amaria R, Davies M, ... ... Allison J, et al. Abstract 4488: Effector B cells and tertiary lymphoid structures predict response to immune checkpoint blockade in solid tumors Cancer Research. 79: 4488-4488. DOI: 10.1158/1538-7445.Am2019-4488  0.432
2019 Campbell M, Martin S, Tam A, Sheth R, Singh S, Ahrar K, Slack Tidwell B, Rao P, Karam J, Wood C, Tannir N, Jonasch E, Gao J, Shah A, Blando J, ... ... Allison J, et al. A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC) Annals of Oncology. 30: v389-v390. DOI: 10.1093/Annonc/Mdz249.059  0.334
2019 Reuben A, Zhang J, Gittelman R, Chiou S, Li J, Fujimoto J, Behrens C, Kheradmand F, Chow C, Bernatchez C, Eterovic A, Benzeno S, Vignali M, Wu XX, Ye Y, ... ... Allison J, et al. MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 14: S293. DOI: 10.1016/J.Jtho.2019.08.589  0.341
2018 Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, ... ... Allison JP, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. PMID 30500073 DOI: 10.1002/Cncr.31896  0.392
2018 Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, ... ... Allison JP, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine. PMID 30420754 DOI: 10.1038/S41591-018-0238-9  0.34
2018 Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, ... ... Allison J, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine. PMID 30297909 DOI: 10.1038/S41591-018-0197-1  0.399
2018 Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery. PMID 30115704 DOI: 10.1158/2159-8290.Cd-18-0367  0.386
2018 Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo JA, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30054281 DOI: 10.1158/1078-0432.Ccr-18-0762  0.504
2018 Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. The Journal of Clinical Investigation. PMID 29905573 DOI: 10.1172/Jci99760  0.54
2018 Daver N, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, Kantarjian H. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. PMID 29487386 DOI: 10.1038/S41375-018-0070-8  0.348
2018 Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Green J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, ... ... Allison JP, et al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunology Research. PMID 29339377 DOI: 10.1158/2326-6066.Cir-17-0356  0.474
2018 Reuben A, Gittelman R, Zhang J, Quek K, Vence LM, Behrens C, Chen R, Fujimoto J, Chow C, Wu X, Allison JP, Sharma P, Zhang J, Lee JJ, Sepesi B, et al. Association of the T-cell receptor landscape with survival in non-small cell lung cancer. Journal of Clinical Oncology. 36: 140-140. DOI: 10.1200/Jco.2018.36.5_Suppl.140  0.429
2018 Nusrat M, Roszik J, Katkhuda R, Menter D, Raghav KPS, Morris VK, Sharma P, Allison JP, Blando JM, Maru DM, Overman MJ, Kopetz S. Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients. Journal of Clinical Oncology. 36: 653-653. DOI: 10.1200/Jco.2018.36.4_Suppl.653  0.364
2018 Williams P, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Lopez JH, Kornblau S, Andreeff M, Bueso-Ramos CE, Blando JM, ... ... Allison JP, et al. Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML. Journal of Clinical Oncology. 36: 7016-7016. DOI: 10.1200/Jco.2018.36.15_Suppl.7016  0.413
2018 De Groot JF, Penas-Prado M, Mandel JJ, O'Brien BJ, Weathers SS, Zhou S, Hunter K, Alfaro-Munoz K, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, Ferguson SD, Yuan Y, ... ... Allison JP, et al. Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. Journal of Clinical Oncology. 36: 2008-2008. DOI: 10.1200/Jco.2018.36.15_Suppl.2008  0.32
2018 Khouri IF, Borin Scutti JA, Milton DR, Nicholas C, Pineda M, Jabbour EJ, Bassett RL, Yadav SS, Vence LM, Allison JP, Gulbis A, Sharma P. Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies Blood. 132: 4585-4585. DOI: 10.1182/Blood-2018-99-117814  0.363
2018 Assi R, Kantarjian HM, Daver NG, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, Kadia TM, Alvarado Y, Jabbour EJ, Konopleva MY, Takahashi K, Kornblau SM, DiNardo CD, Estrov ZE, ... ... Allison JP, et al. Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Blood. 132: 905-905. DOI: 10.1182/Blood-2018-99-116078  0.379
2018 Jaiswal AR, Pudakalakatti S, Dutta P, Liu A, Bartkowiak T, Ager C, Ivan C, Davis RE, Davies MA, Wargo J, Allison JP, Bhattacharya PK, Hong D, Curran MA. Abstract PR08: Metabolic adaptations establish immunotherapy resistance in melanoma Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Pr08  0.394
2018 Sharma N, Allison JP. Abstract B09: TLR1/2 ligand promotes Fc gamma RIV mediated depletion of tumor-infiltrating treg by anti-CTLA-4 antibody and its anti-tumor efficacy Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-B09  0.479
2018 Keung EZ, Glitza IC, Burton E, Amaria RN, Patel SP, Diab A, Yee C, Wong MK, Hwu W, Hwu P, Woodman SE, Tetzlaff MT, Trujillo-Conley N, Milton DR, Davies MA, ... ... Allison JP, et al. Abstract 5711: The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM) Cancer Research. 78: 5711-5711. DOI: 10.1158/1538-7445.Am2018-5711  0.399
2018 Shi LZ, Gao J, Vence L, Brando J, Allison J, Sharma P. Abstract 3570: Adoptive transfer of tumor antigen-specific CTLs requires anti-CTLA-4 and anti-PD-1 to drive tumor eradication Cancer Research. 78: 3570-3570. DOI: 10.1158/1538-7445.Am2018-3570  0.416
2018 Mok S, Duffy CR, Allison JP. Abstract 2984: Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse Cancer Research. 78: 2984-2984. DOI: 10.1158/1538-7445.Am2018-2984  0.523
2017 Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour E, Milton DR, Bassett RL, Vence L, Allison JP, Gulbis AM, Sharma P. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29246938 DOI: 10.1158/1078-0432.Ccr-17-2777  0.389
2017 Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, ... ... Allison JP, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, N.Y.). PMID 29097493 DOI: 10.1126/Science.Aan4236  0.344
2017 Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, ... ... Allison JP, et al. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nature Communications. 8: 451. PMID 28878208 DOI: 10.1038/S41467-017-00449-Z  0.478
2017 Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, ... ... Allison JP, et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine. 2. PMID 28819565 DOI: 10.1038/S41525-017-0013-8  0.405
2017 Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. PMID 28803728 DOI: 10.1016/J.Cell.2017.07.024  0.49
2017 Reuben A, Gittelman RM, Gao J, Zhang J, Yusko E, Wu CJ, Emerson R, Zhang J, Tipton CM, Li J, Quek K, Gopalakrishnan V, Chen R, Vence L, Cascone T, ... ... Allison JP, et al. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery. PMID 28733428 DOI: 10.1158/2159-8290.Cd-17-0256  0.474
2017 Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N. The emerging role of immune checkpoint based approaches in AML and MDS. Leukemia & Lymphoma. 1-13. PMID 28679300 DOI: 10.1080/10428194.2017.1344905  0.36
2017 Nawaf MG, Ulvmar MH, Withers DR, McConnell FM, Gaspal FM, Webb GJ, Jones ND, Yagita H, Allison JP, Lane PJL. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. Journal of Immunology (Baltimore, Md. : 1950). PMID 28646041 DOI: 10.4049/Jimmunol.1700088  0.473
2017 Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, Allison JP, LeBleu VS, Kalluri R. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nature Communications. 8: 15095. PMID 28447602 DOI: 10.1038/Ncomms15095  0.471
2017 Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, ... ... Allison J, et al. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. Journal For Immunotherapy of Cancer. 5: 35. PMID 28428884 DOI: 10.1186/S40425-017-0238-1  0.444
2017 Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine. PMID 28346412 DOI: 10.1038/Nm.4308  0.355
2017 Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, ... ... Allison JP, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine. 9. PMID 28251903 DOI: 10.1126/Scitranslmed.Aah3560  0.424
2017 Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, ... ... Allison J, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. The Lancet. Oncology. PMID 28223062 DOI: 10.1016/S1470-2045(17)30104-3  0.314
2017 Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications. 8: 14340. PMID 28194010 DOI: 10.1038/Ncomms14340  0.392
2017 Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, et al. Metastatic melanoma patient had complete response with clonal expansion after whole brain radiation and PD-1 blockade. Cancer Immunology Research. PMID 28062513 DOI: 10.1158/2326-6066.Cir-16-0223  0.423
2017 Gopalakrishnan V, Spencer C, Reuben A, Karpinets T, Hutchinson D, Hoffman K, Prieto PA, Tetzlaff MT, Lazar A, Davies MA, Gershenwald JE, Jenq RR, Hwu P, Sharma P, Allison JP, et al. Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma. Journal of Clinical Oncology. 35: 2-2. DOI: 10.1200/Jco.2017.35.7_Suppl.2  0.372
2017 Daver NG, Garcia-Manero G, Cortes JE, Basu S, Ravandi F, Kadia TM, Borthakur G, Jabbour E, Dinardo CD, Pemmaraju N, Brandt M, Pierce S, Hussin N, Kornblau SM, Andreeff M, ... ... Allison JP, et al. Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML. Journal of Clinical Oncology. 35: e18505-e18505. DOI: 10.1200/Jco.2017.35.15_Suppl.E18505  0.318
2017 Chen W, Andrews MC, Spencer C, Tawbi HA, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu W, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies MA, ... ... Allison JP, et al. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). Journal of Clinical Oncology. 35: 9579-9579. DOI: 10.1200/Jco.2017.35.15_Suppl.9579  0.44
2017 Daver NG, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Hendrickson S, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia TM, ... ... Allison JP, et al. Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. Journal of Clinical Oncology. 35: 7026-7026. DOI: 10.1200/Jco.2017.35.15_Suppl.7026  0.357
2017 Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis C, Wistuba II, Wargo JA, et al. Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. Journal of Clinical Oncology. 35: 5081-5081. DOI: 10.1200/Jco.2017.35.15_Suppl.5081  0.412
2017 Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C, Gao J, Vence LM, Blando JM, Corn PG, Araujo JC, Zurita AJ, Prokhorova IN, Van Alstine M, Logothetis C, ... ... Allison JP, et al. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). Journal of Clinical Oncology. 35: 5065-5065. DOI: 10.1200/Jco.2017.35.15_Suppl.5065  0.332
2017 Reilley M, Basu S, Katkhuda R, Patterson N, Chen T, Blando JM, Menter D, Maru DM, Allison JP, Kopetz S, Sharma P, Overman MJ. Prognostic implications of TAMs in colorectal cancer hepatic metastases. Journal of Clinical Oncology. 35: 3574-3574. DOI: 10.1200/Jco.2017.35.15_Suppl.3574  0.435
2017 Wargo JA, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Andrews MC, Tetzlaff MT, Lazar A, Hwu P, Hwu W, Glitza IC, Tawbi HA, Patel SP, Lee JE, Davies MA, ... ... Allison JP, et al. Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. Journal of Clinical Oncology. 35: 3008-3008. DOI: 10.1200/Jco.2017.35.15_Suppl.3008  0.347
2017 Ravandi F, Daver N, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, Kadia T, Boddu PC, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, ... ... Allison J, et al. Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia Blood. 130: 815-815. DOI: 10.1182/Blood.V130.Suppl_1.815.815  0.388
2017 Williams P, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Lopez JH, Kornblau S, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, ... ... Allison JP, et al. Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity Blood. 130: 185-185. DOI: 10.1182/Blood.V130.Suppl_1.185.185  0.464
2017 Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour EJ, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, ... ... Allison J, et al. Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML Blood. 130: 1345-1345. DOI: 10.1182/Blood.V130.Suppl_1.1345.1345  0.359
2017 Mok S, Duffy C, Du R, Allison JP. Abstract PR01: Blocking Colony Stimulating Factor 1 Receptor (CSF-1R) and Tropomyosin Receptor Kinase (Trk) improves antitumor efficacy of immunotherapy Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-Pr01  0.402
2017 Allison JP. Abstract IA08: Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for cures Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-Ia08  0.517
2017 Gao J, Karam JA, Wood CG, Matin S, Ahrar K, Jonasch E, Tannir N, Campell M, Ng CS, Slack RS, Rao P, Allison JP, Blando JM, Vence LM, Basu S, et al. Abstract CT083: Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct083  0.373
2017 Wei SC, Levine JH, Pe'er D, Allison JP. Abstract 592: Distinct cellular mechanisms mediate anti-CTLA-4 and anti-PD-1 checkpoint blockade Cancer Research. 77: 592-592. DOI: 10.1158/1538-7445.Am2017-592  0.476
2017 Gopalakrishnan V, Spencer C, Reuben A, Prieto P, Vicente D, Karpinets TV, Hudgens CW, Hutchinson DS, Tetzlaff M, Lazar A, Davies MA, Gershenwald JE, Jenq R, Hwu P, Sharma P, ... Allison J, et al. Abstract 2672: Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome Cancer Research. 77: 2672-2672. DOI: 10.1158/1538-7445.Am2017-2672  0.38
2017 Mok S, Duffy CR, Allison JP. Abstract 1685: Effects of anti-ctla-4 and anti-pd-1 on memory T-cell differentiation and resistance to tumor relapse Cancer Research. 77: 1685-1685. DOI: 10.1158/1538-7445.Am2017-1685  0.524
2017 Reuben A, Gittelman R, Zhang J, Chen R, Quek K, Vence L, Fernandez-Cubelo I, Behrens C, Gao J, Yusko E, Emerson R, Benzeno S, Vignali M, Tipton C, Jalali A, ... ... Allison J, et al. OA 13.05 Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues Journal of Thoracic Oncology. 12: S1780. DOI: 10.1016/J.Jtho.2017.09.404  0.367
2017 Federico L, Haymaker C, Forget M, Vence L, Team I, Sharma P, Allison J, Fang B, Zhang J, Wagner H, Bogatenkova E, Wistuba I, Sepesi B, Heymach J, Gibbons DL, et al. P1.05-028 Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S630-S631. DOI: 10.1016/J.Jtho.2016.11.812  0.334
2016 Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zhang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Research. PMID 27821490 DOI: 10.1158/0008-5472.Can-15-3142  0.4
2016 Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, ... Allison JP, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. PMID 27698113 DOI: 10.1073/Pnas.1611421113  0.512
2016 Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. PMID 27667683 DOI: 10.1016/J.Cell.2016.08.069  0.414
2016 Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. Journal of Hematology & Oncology. 9: 81. PMID 27595932 DOI: 10.1186/S13045-016-0309-7  0.396
2016 Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon SB, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris EA, Brogi E, ... ... Allison JP, et al. Deep Sequencing of T-Cell Receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunology Research. PMID 27587469 DOI: 10.1158/2326-6066.Cir-16-0013  0.463
2016 Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, ... ... Allison JP, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications. 7: 12632. PMID 27572267 DOI: 10.1038/Ncomms12632  0.301
2016 Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nature Communications. 7: 12335. PMID 27498556 DOI: 10.1038/Ncomms12335  0.36
2016 Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, Petaccia De Macedo M, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, ... ... Allison JP, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. PMID 27301722 DOI: 10.1158/2159-8290.Cd-15-1545  0.422
2016 Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, Fu T, Sharma P, Allison JP, Feldman RM. ICOS promotes the function of CD4+ effector T cells during anti-OX40 mediated tumor rejection. Cancer Research. PMID 27197182 DOI: 10.1158/0008-5472.Can-15-3412  0.56
2016 Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, ... ... Allison JP, et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 5: e1136044. PMID 27141370 DOI: 10.1080/2162402X.2015.1136044  0.419
2016 Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C, Vence LM, Logothetis C, Futreal A, Allison JP, Sharma P. A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). Journal of Clinical Oncology. 34: e14506-e14506. DOI: 10.1200/Jco.2016.34.15_Suppl.E14506  0.372
2016 Reilley M, Blando JM, Katkhuda R, Menter D, Sharma P, Allison JP, Kopetz S, Maru DM, Overman MJ. Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC. Journal of Clinical Oncology. 34: 3520-3520. DOI: 10.1200/Jco.2016.34.15_Suppl.3520  0.305
2016 Reilley M, Bailey AM, Subbiah V, Janku F, Naing A, Falchook GS, Karp DD, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Lim J, Bean SA, Bass A, Montez S, ... ... Allison JP, et al. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. Journal of Clinical Oncology. 34: 3054-3054. DOI: 10.1200/Jco.2016.34.15_Suppl.3054  0.449
2016 Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour EJ, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Pemmaraju N, Bueso-Ramos CE, Blando J, ... ... Allison J, et al. Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) Blood. 128: 763-763. DOI: 10.1182/Blood.V128.22.763.763  0.389
2016 Jain N, Basu S, Thompson PA, Ohanian M, Ferrajoli A, Pemmaraju N, Cortes JE, Estrov Z, Burger JA, Neelapu SS, Lopez W, Thakral B, Bueso-Ramos CE, Blando J, O'Brien SM, ... ... Allison J, et al. Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial Blood. 128: 59-59. DOI: 10.1182/Blood.V128.22.59.59  0.339
2016 Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Ning J, Xiao L, Juliana L, Kornblau SM, Konopleva M, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, Blando J, ... Allison J, et al. Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML) Blood. 128: 2900-2900. DOI: 10.1182/Blood.V128.22.2900.2900  0.476
2016 Jain N, Basu S, Thakral B, Burger J, Thompson PA, Ferrajoli A, Estrov Z, Bueso-Ramos CE, Stingo F, Bassett RL, Daver N, Kadia TM, Matthews J, Flores W, Somani N, ... ... Allison J, et al. Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL) Blood. 128: 2012-2012. DOI: 10.1182/Blood.V128.22.2012.2012  0.409
2016 Sharma N, Allison JP. Abstract B143: Fc gamma receptor IV mediated depletionof tumor infiltrating regulatory T cells by anti-CTLA4 antibody is promoted byTLR1/2 agonist and hence its efficacy in anti-tumor combination therapy Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B143  0.492
2016 Mok S, Duffy C, Du R, Allison JP. Abstract A146: Increase antitumor activity of immunotherapy by blocking colony stimulating factor 1 receptor and tropomyosin receptor kinase Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A146  0.405
2016 Massarelli E, Parra ER, Rogriguez-Canales J, Behrens C, Diao L, Blando J, Wang J, Byers LA, Wistuba II, Sharma P, Allison JP, Heymach JV. Abstract A084: High OX-40 expression on the tumor immune infiltrate is a prognostic factor of better survival in non-small cell lung cancer Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A084  0.451
2016 LeBleu VS, Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu C, Simpson T, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, Acosta AD, Sharma P, Heidari P, Mahmood U, ... ... Allison JP, et al. Abstract IA15: Functional diversity of the pancreas tumor stroma Cancer Research. 76. DOI: 10.1158/1538-7445.Fbcr15-Ia15  0.726
2016 Allison JP. Abstract IA02: Immune checkpoint blockade in cancer therapy: New insights and opportunities, and prospects for cures Cancer Research. 76. DOI: 10.1158/1538-7445.Fbcr15-Ia01  0.516
2016 Morris V, Mahvash A, Vence L, Blando J, Wolff RA, Ohinata A, Ohaji C, Allison J, Sharma P, Eng C. Abstract CT131: NCI#9673 phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal: Immunologic correlates of response Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct131  0.482
2016 Cortez MA, Wang X, Ivan C, Schoenhals JE, Niknam S, Li A, Valdecanas D, Allison JP, Sharma P, Overwijk WW, Gomez D, Chang JY, Hahn S, Calin GA, Welsh JW. Abstract 569: MicroRNA-mediated resistance to anti-PD1 therapy in lung cancer Cancer Research. 76: 569-569. DOI: 10.1158/1538-7445.Am2016-569  0.373
2016 Daver N, Basu S, Garcia-Manero G, Cortes J, Ravandi F, Kornblau S, Konopleva M, Andreeff M, Borthakur G, Jain N, Wierda W, Verstovsek S, Ruvolo P, Kadia T, Matthews J, ... ... Allison J, et al. Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML) Cancer Research. 76: 3205-3205. DOI: 10.1158/1538-7445.Am2016-3205  0.431
2016 Reuben A, Spencer CN, Prieto PA, Miller JP, Mao X, Chen W, Cheung H, Jiang H, Haymaker C, Macedo MPD, Garber HR, Chen P, Gopalakrishnan V, Austin-Breneman J, Hudgens CW, ... ... Allison JP, et al. Abstract 2392: Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy Cancer Research. 76: 2392-2392. DOI: 10.1158/1538-7445.Am2016-2392  0.343
2016 Allison JP, Freeman GJ, Gotwals PJ. Part 5: Targeting Cancer Pathways: Understanding Immune Checkpoints Science. 351: 303-303. DOI: 10.1126/Science.351.6270.303-B  0.371
2015 Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, ... ... Allison JP, et al. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell. 28: 831-833. PMID 28843279 DOI: 10.1016/J.Ccell.2015.11.002  0.666
2015 Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports. PMID 26411680 DOI: 10.1016/J.Celrep.2015.08.077  0.45
2015 Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proceedings of the National Academy of Sciences of the United States of America. 112: E5290-9. PMID 26351680 DOI: 10.1073/Pnas.1514418112  0.44
2015 Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. PMID 26310908 DOI: 10.2217/Imt.15.65  0.468
2015 Kreymborg K, Haak S, Murali R, Wei J, Waitz R, Gasteiger G, Savage PA, van den Brink MR, Allison JP. Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. Cancer Immunology Research. 3: 849-54. PMID 26122284 DOI: 10.1158/2326-6066.Cir-15-0100  0.314
2015 Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, ... ... Allison JP, et al. Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery. PMID 26069186 DOI: 10.1158/2159-8290.Cd-14-1236  0.334
2015 Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 161: 205-14. PMID 25860605 DOI: 10.1016/J.Cell.2015.03.030  0.382
2015 Sharma P, Allison JP. The future of immune checkpoint therapy. Science (New York, N.Y.). 348: 56-61. PMID 25838373 DOI: 10.1126/Science.Aaa8172  0.405
2015 Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknect E, Murphy WJ, Serody JS, Munn DH, Freeman GJ, Allison JP, et al. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 125: 3335-46. PMID 25814530 DOI: 10.1182/Blood-2014-09-603357  0.392
2015 Pedicord VA, Cross JR, Montalvo-Ortiz W, Miller ML, Allison JP. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. Journal of Immunology (Baltimore, Md. : 1950). 194: 2089-98. PMID 25624453 DOI: 10.4049/Jimmunol.1402390  0.809
2015 Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research. 25: 208-24. PMID 25582080 DOI: 10.1038/Cr.2015.3  0.373
2015 Reuben A, Spencer C, Roszik J, Miller J, Kwong L, Jiang H, Haymaker C, Chen P, Austin-Breneman J, Roh W, Little L, Cao Y, Garber H, Forget M, Gopalakrishnan V, ... ... Allison J, et al. Molecular and immune heterogeneity in synchronous melanoma metastases Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P262  0.463
2015 Kim DW, Haymaker C, McQuail N, Sirmans E, Spencer C, Glitza I, Amaria R, Woodman S, Patel S, Davies M, Yee C, Hwu W, Bernatchez C, Wargo J, Sharma P, ... Allison J, et al. Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM) Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P137  0.348
2015 Allison J. Cytotoxic T-lymphocyte-associated Protein 4 and Cancer Therapy Blood. 126: SCI-7-SCI-7. DOI: 10.1182/Blood.V126.23.Sci-7.Sci-7  0.513
2015 Page D, Yuan J, Diab A, Dong Z, Ginsberg A, Wong P, Emerson R, Redmond D, Blum B, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, ... ... Allison J, et al. Abstract P2-15-01: Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts) Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P2-15-01  0.527
2015 Skoulidis F, Byers L, Diao L, Papadimitrakopoulou V, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez-Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, ... ... Allison JP, et al. Abstract 968: Co-occurring genomic alterations define major subsets ofKRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities Cancer Research. 75: 968-968. DOI: 10.1158/1538-7445.Am2015-968  0.35
2015 Page D, Yuan J, Dong Z, Ginsberg A, Wong P, Emerson R, Sung J, Comstock C, Mu Z, Solomon S, Diab A, Durack J, Maybody M, Erinjeri J, Brogi E, ... ... Allison J, et al. FEATURED ABSTRACT, Tumor and systemic immune responses to pre-operative cryoablation plus immune therapy with ipilimumab in early stage breast cancer Journal of Vascular and Interventional Radiology. 26: S131. DOI: 10.1016/J.Jvir.2014.12.352  0.341
2014 Yuan J, Ginsberg A, Dong Z, Wong P, Emerson R, Sung JS, Comstock C, Solomon SB, Sacchini V, Morrow M, Brogi E, Morris EA, Patil S, Robins H, Wolchok JD, ... ... Allison JP, et al. Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 64. PMID 28141090 DOI: 10.1200/Jco.2014.32.26_Suppl.64  0.441
2014 Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, ... Allison JP, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 515: 577-81. PMID 25428507 DOI: 10.1038/Nature13988  0.46
2014 Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunology Research. 2: 831-8. PMID 25187273 DOI: 10.1158/2326-6066.Cir-14-0069  0.344
2014 Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. Cancer Immunology Research. 2: 970-80. PMID 25038199 DOI: 10.1158/2326-6066.Cir-14-0104  0.789
2014 Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, ... ... Allison JP, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 25: 719-34. PMID 24856586 DOI: 10.1016/J.Ccr.2014.04.005  0.723
2014 Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. The Journal of Experimental Medicine. 211: 715-25. PMID 24687957 DOI: 10.1084/Jem.20130590  0.749
2014 Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine. 6: 226ra32. PMID 24598590 DOI: 10.1126/Scitranslmed.3008095  0.467
2014 Morris JC, Ramlogan-Steel CA, Yu P, Black BA, Mannan P, Allison JP, Waldmann TA, Steel JC. Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer. Gene Therapy. 21: 393-401. PMID 24572789 DOI: 10.1038/Gt.2014.10  0.366
2014 Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annual Review of Medicine. 65: 185-202. PMID 24188664 DOI: 10.1146/Annurev-Med-092012-112807  0.356
2014 Zamarin D, Holmgaard RB, Subudhi SK, Park J, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. Journal of Clinical Oncology. 32: 3051-3051. DOI: 10.1200/Jco.2014.32.15_Suppl.3051  0.38
2014 Page DB, Diab A, Yuan J, Dong Z, Emerson R, Robins H, Redmond D, Zhao C, Mu Z, Wong P, Solomon SB, Sacchini V, Morrow M, Brogi E, Patil S, ... ... Allison JP, et al. T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi). Journal of Clinical Oncology. 32: 3021-3021. DOI: 10.1200/Jco.2014.32.15_Suppl.3021  0.422
2014 Page DB, McArthur H, Dong Z, Wong P, Emerson R, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, Sung J, Brogi E, Morrow M, Solomon S, ... ... Allison J, et al. Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi) Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P138  0.482
2014 Zamarin D, Holmgaard RB, Plitt T, Allison J, Merghoub T, Wolchok JD. Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P132  0.439
2014 Bello D, Allison J, Ariyan C. B7H3 Expression Correlates with Reduced Infiltration of T cells in Melanoma Tumors and Poor Survival Outcomes Journal of Surgical Research. 186: 564-565. DOI: 10.1016/J.Jss.2013.11.488  0.428
2013 Montalvo-Ortiz W, Scher HI, Allison JP. Dissecting the therapeutic effects of anti-CTLA-4 and ADT in a murine hormone-sensitive prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 61. PMID 28137091 DOI: 10.1200/Jco.2013.31.6_Suppl.61  0.372
2013 Solomon SB, Comstock C, Maybody M, Sacchini V, Durack JC, Blum B, Yuan J, Patil S, Neville DA, Sung JS, Kotin A, Morris EA, Brogi E, Morrow M, Wolchok JD, ... Allison J, et al. A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 67. PMID 28136692 DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3120  0.345
2013 Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunology Research. 1: 229-34. PMID 24777852 DOI: 10.1158/2326-6066.Cir-13-0020  0.444
2013 Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunology Research. 1: 235-44. PMID 24396833 DOI: 10.1158/2326-6066.Cir-13-0068  0.543
2013 Malchow S, Leventhal DS, Nishi S, Fischer BI, Shen L, Paner GP, Amit AS, Kang C, Geddes JE, Allison JP, Socci ND, Savage PA. Re: Aire-dependent thymic development of tumor-associated regulatory T cells Journal of Urology. 190: 1954. PMID 24120816 DOI: 10.1016/J.Juro.2013.07.027  0.458
2013 Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. The Journal of Experimental Medicine. 210: 1695-710. PMID 23897981 DOI: 10.1084/Jem.20130579  0.784
2013 Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Annals of the New York Academy of Sciences. 1291: 1-13. PMID 23772560 DOI: 10.1111/Nyas.12180  0.374
2013 Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. The Journal of Experimental Medicine. 210: 1389-402. PMID 23752227 DOI: 10.1084/Jem.20130066  0.525
2013 Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. The Journal of Experimental Medicine. 210: 743-55. PMID 23547098 DOI: 10.1084/Jem.20121190  0.544
2013 Malchow S, Leventhal DS, Nishi S, Fischer BI, Shen L, Paner GP, Amit AS, Kang C, Geddes JE, Allison JP, Socci ND, Savage PA. Aire-dependent thymic development of tumor-associated regulatory T cells. Science (New York, N.Y.). 339: 1219-24. PMID 23471412 DOI: 10.1126/Science.1233913  0.5
2013 Corse E, Gottschalk RA, Park JS, Sepulveda MA, Loke P, Sullivan TJ, Johnson LK, Allison JP. Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand. Journal of Immunology (Baltimore, Md. : 1950). 190: 526-30. PMID 23248264 DOI: 10.4049/Jimmunol.1202621  0.729
2013 Zamarin D, Holmgaard R, Subudhi S, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O9  0.454
2013 Allison JP. Abstract IA19: Immune checkpoint blockade in cancer therapy: New insights and opportunities Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Tumang15-Ia19  0.493
2013 Callahan MK, Wolchok JD, Allison JP, Sharma P. Immune co-signaling to treat cancer Cancer Immunotherapy: Paradigms, Practice and Promise. 2147483647: 211-280. DOI: 10.1007/978-1-4614-4732-0_8  0.421
2012 Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, ... ... Allison JP, et al. Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine. 10: 205. PMID 23034130 DOI: 10.1186/1479-5876-10-205  0.385
2012 Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 9: 827-43. PMID 22996231 DOI: 10.1007/S13311-012-0144-7  0.518
2012 Lee JS, Scandiuzzi L, Ray A, Wei J, Hofmeyer KA, Abadi YM, Loke P, Lin J, Yuan J, Serreze DV, Allison JP, Zang X. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. Journal of Immunology (Baltimore, Md. : 1950). 189: 4165-74. PMID 22972920 DOI: 10.4049/Jimmunol.1201241  0.461
2012 Waitz R, Fassò M, Allison JP. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology. 1: 544-546. PMID 22754781 DOI: 10.4161/Onci.19442  0.489
2012 Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibits in trans. Journal of Immunology (Baltimore, Md. : 1950). 189: 1123-7. PMID 22753941 DOI: 10.4049/Jimmunol.1200695  0.521
2012 Zhang M, Ju W, Yao Z, Yu P, Wei BR, Simpson RM, Waitz R, Fassò M, Allison JP, Waldmann TA. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. Journal of Immunology (Baltimore, Md. : 1950). 188: 6156-64. PMID 22593619 DOI: 10.4049/Jimmunol.1102604  0.398
2012 Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. Plos One. 7: e35222. PMID 22493742 DOI: 10.1371/Journal.Pone.0035222  0.424
2012 Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proceedings of the National Academy of Sciences of the United States of America. 109: 6187-92. PMID 22474386 DOI: 10.1073/Pnas.1203479109  0.506
2012 Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, ... ... Allison JP, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. The New England Journal of Medicine. 366: 925-31. PMID 22397654 DOI: 10.1056/Nejmoa1112824  0.474
2012 Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 482: 400-4. PMID 22318521 DOI: 10.1038/Nature10755  0.463
2012 Gottschalk RA, Hathorn MM, Beuneu H, Corse E, Dustin ML, Altan-Bonnet G, Allison JP. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proceedings of the National Academy of Sciences of the United States of America. 109: 881-6. PMID 22223661 DOI: 10.1073/Pnas.1119763109  0.818
2012 Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. Journal of Immunology (Baltimore, Md. : 1950). 188: 976-80. PMID 22198953 DOI: 10.4049/Jimmunol.1102964  0.755
2012 Waitz R, Solomon SB, Petre EN, Trumble AE, Fassò M, Norton L, Allison JP. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Research. 72: 430-9. PMID 22108823 DOI: 10.1158/0008-5472.Can-11-1782  0.529
2012 Gottschalk RA, Corse E, Allison JP. Response to Comment on “Expression of Helios in Peripherally Induced Foxp3+ Regulatory T Cells” The Journal of Immunology. 189: 500.2-501. DOI: 10.4049/Jimmunol.1290034  0.76
2012 Diab A, Solomon S, Allison J, Norton L, McArthur H. Interventional immunotherapy in breast cancer Breast Cancer Management. 1: 257-260. DOI: 10.2217/Bmt.12.44  0.336
2012 Diab A, McArthur H, Solomon S, Comstock C, Maybody M, Sacchini V, Durack J, Gucalp A, Yuan J, Patil S, Thorne A, Sung J, Kotin A, Morris E, Brogi E, ... ... Allison J, et al. Abstract OT3-1-01: A pilot study of single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer scheduled for mastectomy Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Ot3-1-01  0.402
2011 Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, et al. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. 9: 214. PMID 22168571 DOI: 10.1186/1479-5876-9-214  0.309
2011 Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nature Reviews. Cancer. 11: 805-12. PMID 22020206 DOI: 10.1038/Nrc3153  0.36
2011 Krummel MF, Allison JP. Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The journal of experimental medicine. 1995. 182: 459-465. Journal of Immunology (Baltimore, Md. : 1950). 187: 3459-65. PMID 21934097  0.332
2011 Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, ... Allison JP, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences of the United States of America. 108: 16723-8. PMID 21933959 DOI: 10.1073/Pnas.1110814108  0.485
2011 Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, ... ... Allison JP, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine. 17: 1094-100. PMID 21873989 DOI: 10.1038/Nm.2438  0.543
2011 Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, Allison JP, Li MO. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity. 35: 123-34. PMID 21757379 DOI: 10.1016/J.Immuni.2011.04.019  0.475
2011 Wei J, Loke P, Zang X, Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. The Journal of Experimental Medicine. 208: 1683-94. PMID 21727190 DOI: 10.1084/Jem.20100639  0.46
2011 Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. Plos One. 6: e19499. PMID 21559358 DOI: 10.1371/Journal.Pone.0019499  0.536
2011 Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. Journal of Immunology (Baltimore, Md. : 1950). 186: 5039-45. PMID 21505216 DOI: 10.4049/Jimmunol.1003650  0.769
2011 Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunological Reviews. 241: 104-18. PMID 21488893 DOI: 10.1111/J.1600-065X.2011.01007.X  0.766
2011 Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunology, Immunotherapy : Cii. 60: 1137-46. PMID 21465316 DOI: 10.1007/S00262-011-1011-9  0.512
2011 Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proceedings of the National Academy of Sciences of the United States of America. 108: 266-71. PMID 21173239 DOI: 10.1073/Pnas.1016791108  0.818
2011 Ariyan CE, Quezada S, Corse E, Montalvo W, Allison J. Abstract 1786: Improved survival with gemcitabine and CTLA-4 blockade in a murine model of prostate cancer Cancer Research. 71: 1786-1786. DOI: 10.1158/1538-7445.Am2011-1786  0.411
2010 Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Seminars in Oncology. 37: 473-84. PMID 21074063 DOI: 10.1053/J.Seminoncol.2010.09.001  0.456
2010 Corse E, Gottschalk RA, Krogsgaard M, Allison JP. Attenuated T cell responses to a high-potency ligand in vivo. Plos Biology. 8. PMID 20856903 DOI: 10.1371/Journal.Pbio.1000481  0.789
2010 Gottschalk RA, Corse E, Allison JP. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. The Journal of Experimental Medicine. 207: 1701-11. PMID 20660617 DOI: 10.1084/Jem.20091999  0.747
2010 Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J, Allison JP. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 23: 1104-12. PMID 20495537 DOI: 10.1038/Modpathol.2010.95  0.343
2010 Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2861-71. PMID 20460488 DOI: 10.1158/1078-0432.Ccr-10-0569  0.373
2010 Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2781-91. PMID 20460483 DOI: 10.1158/1078-0432.Ccr-09-3243  0.531
2010 Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America. 107: 4275-80. PMID 20160101 DOI: 10.1073/Pnas.0915174107  0.464
2010 Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. The Journal of Experimental Medicine. 207: 637-50. PMID 20156971 DOI: 10.1084/Jem.20091918  0.837
2010 Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 116: 1767-75. PMID 20143434 DOI: 10.1002/Cncr.24951  0.414
2010 Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Current Opinion in Immunology. 22: 326-32. PMID 20116985 DOI: 10.1016/J.Coi.2010.01.001  0.775
2010 Jayaraj R, Piedrafita D, Dynon K, Grams R, Spithill TW, Smooker PM, Ruiz S, Pascal N, Dalencon F, Danve B, Burdin N, Rokbi B, Zahedifard F, Rafati S, Bolhassani A, ... ... Allison JP, et al. Vaccination and immunotherapy against bacteria, fungi and parasites (WS-048) Chairpersons: Hajime Hisaeda, Miodrag Colic International Immunology. 22. DOI: 10.1093/Intimm/Dxq312  0.73
2009 Sharma P, Tsavachidou D, Kamat A, Ng Tang D, Chen H, Fu T, Troncoso P, Wolchok J, Logothetis CJ, Allison JP. Immunologic impact of anti-CTLA-4 therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3019. PMID 27962056 DOI: 10.1200/Jco.2009.27.15_Suppl.3019  0.431
2009 Thompson RH, Kwon ED, Allison JP. Inhibitors of B7-CD28 costimulation in urologic malignancies Immunotherapy. 1: 129-139. PMID 20445772 DOI: 10.2217/1750743X.1.1.129  0.514
2009 Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy. 11: 912-22. PMID 19903103 DOI: 10.3109/14653240903136987  0.491
2009 Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Research. 69: 7747-55. PMID 19738077 DOI: 10.1158/0008-5472.Can-08-3289  0.446
2009 Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5323-37. PMID 19723653 DOI: 10.1158/1078-0432.Ccr-09-0737  0.362
2009 Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clinical and Experimental Immunology. 157: 9-19. PMID 19659765 DOI: 10.1111/J.1365-2249.2009.03912.X  0.437
2009 Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. The Journal of Experimental Medicine. 206: 1717-25. PMID 19581407 DOI: 10.1084/Jem.20082492  0.552
2009 Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunological Reviews. 229: 67-87. PMID 19426215 DOI: 10.1111/J.1600-065X.2009.00763.X  0.517
2008 Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Blute ML, Russo P, Kwon ED, Allison JP. Evaluation of soluble B7x as a serum marker in patients with clear cell renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5052. PMID 27948878 DOI: 10.1200/Jco.2008.26.15_Suppl.5052  0.365
2008 Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, ... ... Allison JP, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proceedings of the National Academy of Sciences of the United States of America. 105: 20410-5. PMID 19074257 DOI: 10.1073/Pnas.0810114105  0.519
2008 Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunological Reviews. 224: 141-65. PMID 18759925 DOI: 10.1111/J.1600-065X.2008.00649.X  0.499
2008 Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. The Journal of Experimental Medicine. 205: 2125-38. PMID 18725522 DOI: 10.1084/Jem.20080099  0.796
2008 Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Research. 68: 6054-8. PMID 18676826 DOI: 10.1158/0008-5472.Can-08-0869  0.342
2008 Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 112: 1175-83. PMID 18523152 DOI: 10.1182/Blood-2007-11-125435  0.525
2008 Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proceedings of the National Academy of Sciences of the United States of America. 105: 3509-14. PMID 18303116 DOI: 10.1073/Pnas.0712269105  0.479
2008 Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, ... ... Allison JP, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 105: 3005-10. PMID 18287062 DOI: 10.1073/Pnas.0712237105  0.5
2008 Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer Cancer Research. 68: 889-892. PMID 18245491 DOI: 10.1158/0008-5472.Can-07-3095  0.363
2008 Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity Cancer Immunology, Immunotherapy. 57: 1263-1270. PMID 18236040 DOI: 10.1007/S00262-008-0451-3  0.474
2008 Savage PA, Vosseller K, Kang C, Larimore K, Riedel E, Wojnoonski K, Jungbluth AA, Allison JP. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science (New York, N.Y.). 319: 215-20. PMID 18187659 DOI: 10.1126/Science.1148886  0.516
2007 Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proceedings of the National Academy of Sciences of the United States of America. 104: 19458-63. PMID 18042703 DOI: 10.1073/Pnas.0709802104  0.33
2007 Pentcheva-Hoang T, Chen L, Pardoll DM, Allison JP. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proceedings of the National Academy of Sciences of the United States of America. 104: 17765-70. PMID 17968013 DOI: 10.1073/Pnas.0708767104  0.414
2007 Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5271-9. PMID 17875755 DOI: 10.1158/1078-0432.Ccr-07-1030  0.51
2007 Loke P, Gallagher I, Nair MG, Zang X, Brombacher F, Mohrs M, Allison JP, Allen JE. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. Journal of Immunology (Baltimore, Md. : 1950). 179: 3926-36. PMID 17785830 DOI: 10.4049/Jimmunol.179.6.3926  0.399
2007 Peggs KS, Segal NH, Allison JP. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell. 12: 192-9. PMID 17785201 DOI: 10.1016/J.Ccr.2007.08.023  0.386
2007 Enzler T, Gillessen S, Dougan M, Allison JP, Neuberg D, Oble DA, Mihm M, Dranoff G. Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood. 110: 954-61. PMID 17483299 DOI: 10.1182/Blood-2006-08-043786  0.326
2007 Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2158-67. PMID 17404100 DOI: 10.1158/1078-0432.Ccr-06-2070  0.503
2007 Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Seminars in Oncology. 34: 165-72. PMID 17382800 DOI: 10.1053/J.Seminoncol.2006.12.004  0.364
2007 Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1810-5. PMID 17363537 DOI: 10.1158/1078-0432.Ccr-06-2318  0.446
2007 Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E, Zencheck WD, Lary JW, Cole JL, Deng H, Xiao H, Dilorenzo TP, Allison JP, Nathenson SG, Almo SC. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity. 26: 311-21. PMID 17363302 DOI: 10.1016/J.Immuni.2007.01.016  0.423
2007 Peggs KS, Quezada SA, Simpson TR, Allison JP. Dissociation of Systemic and Local Anti-Tumor Immunity Following Depletion of Regulatory T Cells Limits Therapeutic Activity in Established Tumors. Blood. 110: 286-286. DOI: 10.1182/Blood.V110.11.286.286  0.787
2006 Zang X, Allison JP. To be or not to be B7. The Journal of Clinical Investigation. 116: 2590-3. PMID 17016555 DOI: 10.1172/Jci30103  0.4
2006 Zang X, Loke P, Kim J, Wojnoonski K, Kusdra L, Allison JP. A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics. 88: 841-5. PMID 17014982 DOI: 10.1016/J.Ygeno.2006.08.012  0.412
2006 Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urologic Oncology. 24: 442-7. PMID 16962497 DOI: 10.1016/J.Urolonc.2005.08.011  0.54
2006 Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. Journal of Immunology (Baltimore, Md. : 1950). 177: 1052-61. PMID 16818761 DOI: 10.4049/Jimmunol.177.2.1052  0.493
2006 Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. The Journal of Clinical Investigation. 116: 1935-45. PMID 16778987 DOI: 10.1172/Jci27745  0.538
2006 Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Advances in Immunology. 90: 297-339. PMID 16730267 DOI: 10.1016/S0065-2776(06)90008-X  0.475
2006 Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Current Opinion in Immunology. 18: 206-13. PMID 16464564 DOI: 10.1016/J.Coi.2006.01.011  0.493
2006 Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 439: 682-7. PMID 16382236 DOI: 10.1038/Nature04444  0.494
2005 Puré E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nature Immunology. 6: 1207-10. PMID 16369561 DOI: 10.1038/Ni1205-1207  0.34
2005 Williams JA, Hathcock KS, Klug D, Harada Y, Choudhury B, Allison JP, Abe R, Hodes RJ. Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint. Journal of Immunology (Baltimore, Md. : 1950). 175: 4199-207. PMID 16177059 DOI: 10.4049/Jimmunol.175.7.4199  0.388
2005 Peggs KS, Allison JP. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. British Journal of Haematology. 130: 809-24. PMID 16156851 DOI: 10.1111/J.1365-2141.2005.05627.X  0.457
2005 Loke P, Zang X, Hsuan L, Waitz R, Locksley RM, Allen JE, Allison JP. Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. Proceedings of the National Academy of Sciences of the United States of America. 102: 9872-7. PMID 15994233 DOI: 10.1073/Pnas.0503961102  0.432
2005 Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP, Lanier LL. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 174: 1922-31. PMID 15699119 DOI: 10.4049/Jimmunol.174.4.1922  0.492
2005 Allison JP, McIntyre BW, Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. 1982. Journal of Immunology (Baltimore, Md. : 1950). 174: 1144-51. PMID 15661866  0.327
2005 Allison JP. CTLA-4 BLOCKADE IN TUMOR IMMUNOTHERAPY Cold Spring Harbor Symposia On Quantitative Biology. 70: 1-1. DOI: 10.1101/Sqb.2004.70.2  0.337
2004 Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Augmentation of T cell levels and responses induced by androgen deprivation. Journal of Immunology (Baltimore, Md. : 1950). 173: 6098-108. PMID 15528346 DOI: 10.4049/Jimmunol.173.10.6098  0.485
2004 Loke P, Allison JP. Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. Arthritis Research & Therapy. 6: 208-14. PMID 15380035 DOI: 10.1186/Ar1225  0.51
2004 Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 21: 401-13. PMID 15357951 DOI: 10.1016/J.Immuni.2004.06.017  0.644
2004 Stohl W, Xu D, Kim KS, David CS, Allison JP. MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). International Immunology. 16: 895-904. PMID 15136557 DOI: 10.1093/Intimm/Dxh091  0.408
2004 Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 22: 1700-8. PMID 15068853 DOI: 10.1016/J.Vaccine.2003.10.048  0.47
2004 Mamura M, Lee W, Sullivan TJ, Felici A, Sowers AL, Allison JP, Letterio JJ. CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1. Blood. 103: 4594-601. PMID 15016653 DOI: 10.1182/Blood-2003-08-2897  0.371
2004 Taylor PA, Lees CJ, Fournier S, Allison JP, Sharpe AH, Blazar BR. B7 Expression on T Cells Down-Regulates Immune Responses through CTLA-4 Ligation via R-T Interactions Journal of Immunology. 172: 34-39. PMID 14688306 DOI: 10.4049/Jimmunol.172.1.34  0.468
2004 Taylor PA, Lees CJ, Fournier S, Allison JP, Sharpe AH, Blazar BR. B7 Expression on T Cells Down-Regulates Immune Responses through CTLA-4 Ligation via R-T Interactions. The Journal of Immunology. 173: 2199.2-2199. DOI: 10.4049/jimmunol.173.3.2199-a  0.352
2004 Taylor PA, Lees CJ, Fournier S, Allison JP, Sharpe AH, Blazer BR. B7 Expression on T Cells Down-Regulates Immune Responses through CTLA-4 Ligation via R-T Interactions. The Journal of Immunology. 172: 5128.2-5128. DOI: 10.4049/jimmunol.172.8.5128-b  0.352
2004 Pardoll D, Allison J. Translation of cancer immunotherapies Nature Medicine. 10: 1155-1155. DOI: 10.1038/Nm1104-1155A  0.327
2003 Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proceedings of the National Academy of Sciences of the United States of America. 100: 10388-92. PMID 12920180 DOI: 10.1073/Pnas.1434299100  0.488
2003 Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America. 100: 8372-7. PMID 12826605 DOI: 10.1073/Pnas.1533209100  0.489
2003 Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nature Immunology. 4: 670-9. PMID 12796776 DOI: 10.1038/Ni944  0.487
2003 Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, ... Allison JP, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America. 100: 4712-7. PMID 12682289 DOI: 10.1073/Pnas.0830997100  0.48
2003 Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Prostate cancer: advances in immunotherapy. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 17: 131-8. PMID 12641491 DOI: 10.2165/00063030-200317020-00005  0.418
2002 Prilliman KR, Lemmens EE, Palioungas G, Wolfe TG, Allison JP, Sharpe AH, Schoenberger SP. Cutting edge: A crucial role for B7-CD28 in transmitting T help from APC to CTL Journal of Immunology. 169: 4094-4097. PMID 12370335 DOI: 10.4049/Jimmunol.169.8.4094  0.382
2002 Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunology. 3: 611-8. PMID 12087419 DOI: 10.1038/Ni0702-611  0.767
2002 Chambers CA, Kang J, Wu Y, Held W, Raulet DH, Allison JP. The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. Blood. 99: 4509-16. PMID 12036882 DOI: 10.1182/Blood.V99.12.4509  0.507
2002 Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proceedings of the National Academy of Sciences of the United States of America. 99: 3013-7. PMID 11867713 DOI: 10.1073/Pnas.042684699  0.461
2002 Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 16: 23-35. PMID 11825563 DOI: 10.1016/S1074-7613(01)00259-X  0.745
2001 Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED. The TRAMP mouse as a model for prostate cancer. Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. Unit 20.5. PMID 18432778 DOI: 10.1002/0471142735.Im2005S45  0.313
2001 Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. The Journal of Experimental Medicine. 194: 823-32. PMID 11560997 DOI: 10.1084/Jem.194.6.823  0.565
2001 van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. The Journal of Experimental Medicine. 194: 481-9. PMID 11514604 DOI: 10.1084/Jem.194.4.481  0.549
2001 Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 409: 97-101. PMID 11343121 DOI: 10.1038/35051100  0.538
2001 Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy Annual Review of Immunology. 19: 565-594. PMID 11244047 DOI: 10.1146/Annurev.Immunol.19.1.565  0.752
2001 Sullivan TJ, Letterio JJ, Van Elsas A, Mamura M, Van Amelsfort J, Sharpe S, Metzler B, Chambers CA, Allison JP. Lack of a role for transforming growth factor-β in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation Proceedings of the National Academy of Sciences of the United States of America. 98: 2587-2592. PMID 11226283 DOI: 10.1073/Pnas.051632398  0.391
2000 Kuhns MS, Epshteyn V, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America. 97: 12711-6. PMID 11050166 DOI: 10.1073/Pnas.220423597  0.469
2000 Luhder F, Chambers C, Allison JP, Benoist C, Mathis D. Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proceedings of the National Academy of Sciences of the United States of America. 97: 12204-9. PMID 11035773 DOI: 10.1073/Pnas.200348397  0.48
2000 Yu X, Fournier S, Allison JP, Sharpe AH, Hodes RJ. The role of B7 costimulation in CD4/CD8 T cell homeostasis Journal of Immunology. 164: 3543-3553. PMID 10725709 DOI: 10.4049/Jimmunol.164.7.3543  0.443
2000 Piganelli JD, Poulin M, Martin T, Allison JP, Haskins K. Cytotoxic T lymphocyte antigen 4 (CD152)regulates self-reactive T cells in BALB/c but not in the autoimmune nod mouse Journal of Autoimmunity. 14: 123-131. PMID 10677243 DOI: 10.1006/Jaut.1999.0353  0.507
1999 Chambers CA, Allison JP. CTLA-4 - The costimulatory molecule that doesn't: Regulation of T-cell responses by inhibition Cold Spring Harbor Symposia On Quantitative Biology. 64: 303-312. PMID 11232300 DOI: 10.1101/Sqb.1999.64.303  0.46
1999 Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proceedings of the National Academy of Sciences of the United States of America. 96: 15074-9. PMID 10611340 DOI: 10.1073/Pnas.96.26.15074  0.375
1999 Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance Proceedings of the National Academy of Sciences of the United States of America. 96: 11476-11481. PMID 10500201 DOI: 10.1073/Pnas.96.20.11476  0.504
1999 van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. The Journal of Experimental Medicine. 190: 355-66. PMID 10430624 DOI: 10.1084/Jem.190.3.355  0.488
1999 Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4+ T cell responses Proceedings of the National Academy of Sciences of the United States of America. 96: 8603-8608. PMID 10411922 DOI: 10.1073/Pnas.96.15.8603  0.513
1999 Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. Journal of Immunology (Baltimore, Md. : 1950). 162: 5813-20. PMID 10229815  0.304
1999 Chambers CA, Allison JP. Costimulatory regulation of T cell function Current Opinion in Cell Biology. 11: 203-210. PMID 10209159 DOI: 10.1016/S0955-0674(99)80027-1  0.487
1998 Chambers CA, Sullivan TJ, Truong T, Allison JP. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells European Journal of Immunology. 28: 3137-3143. PMID 9808182 DOI: 10.1002/(Sici)1521-4141(199810)28:10<3137::Aid-Immu3137>3.0.Co;2-X  0.514
1998 Allison JP, Chambers C, Hurwitz A, Sullivan T, Boitel B, Fournier S, Brunner M, Krummel M. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Foundation Symposium. 215: 92-8; discussion 98-. PMID 9760573 DOI: 10.1002/9780470515525.Ch7  0.504
1998 Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 95: 10067-71. PMID 9707601 DOI: 10.1073/Pnas.95.17.10067  0.555
1998 Rathmell JC, Fournier S, Weintraub BC, Allison JP, Goodnow CC. Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. The Journal of Experimental Medicine. 188: 651-9. PMID 9705947 DOI: 10.1084/Jem.188.4.651  0.457
1998 Hurwitz AA, Townsend SE, Yu TF, Wallin JA, Allison JP. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. International Journal of Cancer. Journal International Du Cancer. 77: 107-13. PMID 9639401 DOI: 10.1002/(Sici)1097-0215(19980703)77:1<107::Aid-Ijc17>3.0.Co;2-B  0.429
1998 Lühder F, Höglund P, Allison JP, Benoist C, Mathis D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. The Journal of Experimental Medicine. 187: 427-32. PMID 9449722 DOI: 10.1084/Jem.187.3.427  0.374
1997 Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity. 7: 885-95. PMID 9430233 DOI: 10.1016/S1074-7613(00)80406-9  0.453
1997 Chambers CA, Cado D, Truong T, Allison JP. Thymocyte development is normal in CTLA-4-deficient mice Proceedings of the National Academy of Sciences of the United States of America. 94: 9296-9301. PMID 9256476 DOI: 10.1073/Pnas.94.17.9296  0.44
1997 Zhang Y, Allison JP. Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proceedings of the National Academy of Sciences of the United States of America. 94: 9273-8. PMID 9256472 DOI: 10.1073/Pnas.94.17.9273  0.32
1997 Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 94: 8099-103. PMID 9223321 DOI: 10.1073/Pnas.94.15.8099  0.459
1997 Liao XC, Fournier S, Killeen N, Weiss A, Allison JP, Littman DR. Itk negatively regulates induction of T cell proliferation by CD28 costimulation Journal of Experimental Medicine. 186: 221-228. PMID 9221751 DOI: 10.1084/Jem.186.2.221  0.448
1997 Chambers CA, Allison JP. Co-stimulation in T cell responses Current Opinion in Immunology. 9: 396-404. PMID 9203422 DOI: 10.1016/S0952-7915(97)80087-8  0.514
1997 Fournier S, Rathmell JC, Goodnow CC, Allison JP. T cell-mediated elimination of B7.2 transgenic B cells. Immunity. 6: 327-39. PMID 9075933 DOI: 10.1016/S1074-7613(00)80335-0  0.413
1997 Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. Journal of Neuroimmunology. 73: 57-62. PMID 9058759 DOI: 10.1016/S0165-5728(96)00168-3  0.404
1997 Brunner M, Chan F, Hinkel C, Hanke J, Winoto A, Allison J. The role of CTLA-4 during the activation of resting CD4+ T-cells Immunology Letters. 56: 56-57. DOI: 10.1016/S0165-2478(97)85213-3  0.355
1996 Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S, Cassell D, Brunner M, Allison JP. The role of CTLA-4 in the regulation and initiation of T-Cell responses Immunological Reviews. 27-46. PMID 9010718 DOI: 10.1111/J.1600-065X.1996.Tb00919.X  0.459
1996 Chambers CA, Allison JP. The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signal transduction European Journal of Immunology. 26: 3224-3229. PMID 8977326 DOI: 10.1002/Eji.1830261257  0.438
1996 Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. The Journal of Experimental Medicine. 183: 2533-40. PMID 8676074 DOI: 10.1084/Jem.183.6.2533  0.49
1996 Krummel MF, Sullivan TJ, Allison JP. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. International Immunology. 8: 519-23. PMID 8671638 DOI: 10.1093/Intimm/8.4.519  0.453
1996 Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (New York, N.Y.). 271: 1734-6. PMID 8596936 DOI: 10.1126/Science.271.5256.1734  0.513
1995 Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Current Opinion in Immunology. 7: 682-6. PMID 8573312 DOI: 10.1016/0952-7915(95)80077-8  0.52
1995 Zhang Y, Cado D, Asarnow DM, Komori T, Alt FW, Raulet DH, Allison JP. The role of short homology repeats and TdT in generation of the invariant gamma delta antigen receptor repertoire in the fetal thymus. Immunity. 3: 439-47. PMID 7584135 DOI: 10.1016/1074-7613(95)90173-6  0.429
1995 Robey E, Allison JP. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules Immunology Today. 16: 306-310. PMID 7576059 DOI: 10.1016/0167-5699(95)80140-5  0.487
1995 Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The Journal of Experimental Medicine. 182: 459-65. PMID 7543139 DOI: 10.1084/Jem.182.2.459  0.511
1995 Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science (New York, N.Y.). 270: 932-3. PMID 7481795 DOI: 10.1126/Science.270.5238.932  0.464
1994 Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Research. 54: 6477-83. PMID 7527298  0.322
1994 Allison JP. CD28-B7 interactions in T-cell activation Current Opinion in Immunology. 6: 414-419. PMID 7522466 DOI: 10.1016/0952-7915(94)90120-1  0.522
1994 Nandi D, Gross JA, Allison JP. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. Journal of Immunology (Baltimore, Md. : 1950). 152: 3361-9. PMID 7511644  0.316
1993 Wells FB, Tatsumi Y, Bluestone JA, Hedrick SM, Allison JP, Matis LA. Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage. The Journal of Experimental Medicine. 177: 1061-70. PMID 8459203 DOI: 10.1084/Jem.177.4.1061  0.367
1993 Sagerström CG, Kerr EM, Allison JP, Davis MM. Activation and differentiation requirements of primary T cells in vitro. Proceedings of the National Academy of Sciences of the United States of America. 90: 8987-91. PMID 8415642 DOI: 10.1073/Pnas.90.19.8987  0.495
1993 Allison JP. Gamma delta T-cell development. Current Opinion in Immunology. 5: 241-6. PMID 8389558 DOI: 10.1016/0952-7915(93)90011-G  0.453
1993 Gramzinski RA, Adams E, Gross JA, Goodman TG, Allison JP, Lefrançois L. T cell receptor-triggered activation of intraepithelial lymphocytes in vitro. International Immunology. 5: 145-53. PMID 8383994 DOI: 10.1093/Intimm/5.2.145  0.35
1993 Leclercq G, Plum J, Nandi D, De Smedt M, Allison JP. Intrathymic differentiation of V gamma 3 T cells. The Journal of Experimental Medicine. 178: 309-15. PMID 8315386 DOI: 10.1084/Jem.178.1.309  0.347
1993 Nandi D, Allison JP. Characterization of neutrophils and T lymphocytes associated with the murine vaginal epithelium. Regional Immunology. 5: 332-8. PMID 8068536  0.394
1993 Clements JL, Winslow G, Donahue C, Cooper SM, Allison JP, Budd RC. Co-stimulation via CD28 induces activation of a refractory subset of MRL-lpr/lpr T lymphocytes. International Immunology. 5: 1451-60. PMID 7903158 DOI: 10.1093/Intimm/5.11.1451  0.425
1993 Page DM, Kane LP, Allison JP, Hedrick SM. Two signals are required for negative selection of CD4+CD8+ thymocytes. Journal of Immunology (Baltimore, Md. : 1950). 151: 1868-80. PMID 7688388  0.323
1993 Harding FA, Allison JP. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. The Journal of Experimental Medicine. 177: 1791-6. PMID 7684435 DOI: 10.1084/Jem.177.6.1791  0.428
1993 Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (New York, N.Y.). 259: 368-70. PMID 7678351 DOI: 10.1126/Science.7678351  0.558
1992 Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones Nature. 356: 607-609. PMID 1313950 DOI: 10.1038/356607A0  0.521
1991 Allison JP, Havran WL. The immunobiology of T cells with invariant gamma delta antigen receptors. Annual Review of Immunology. 9: 679-705. PMID 1832874 DOI: 10.1146/Annurev.Iy.09.040191.003335  0.459
1991 Iwashima M, Green A, Bonyhadi M, Davis MM, Allison JP, Chien YH. Expression of a fetal gamma delta T-cell receptor in adult mice triggers a non-MHC-linked form of selective depletion. International Immunology. 3: 385-93. PMID 1831656 DOI: 10.1093/Intimm/3.4.385  0.41
1991 Havran WL, Chien YH, Allison JP. Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science (New York, N.Y.). 252: 1430-2. PMID 1828619 DOI: 10.1126/Science.1828619  0.446
1991 Havran WL, Carbone A, Allison JP. Murine T cells with invariant gamma delta antigen receptors: origin, repertoire, and specificity. Seminars in Immunology. 3: 89-97. PMID 1716172  0.348
1991 Nandi D, Allison JP. Phenotypic analysis and gamma delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. Journal of Immunology (Baltimore, Md. : 1950). 147: 1773-8. PMID 1679835  0.354
1990 Gross JA, St John T, Allison JP. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. Journal of Immunology (Baltimore, Md. : 1950). 144: 3201-10. PMID 2157764  0.354
1990 Allison JP, Raulet DH. The immunobiology of γδ+ T cells Seminars in Immunology. 2: 59-65. PMID 2151798  0.348
1990 Havran WL, Allison JP. Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. Nature. 344: 68-70. PMID 1968230 DOI: 10.1038/344068A0  0.372
1989 Havran WL, Poenie M, Tigelaar RE, Tsien RY, Allison JP. Phenotypic and functional analysis of gamma delta T cell receptor-positive murine dendritic epidermal clones. Journal of Immunology (Baltimore, Md. : 1950). 142: 1422-8. PMID 2783942  0.3
1989 Havran WL, Grell S, Duwe G, Kimura J, Wilson A, Kruisbeek AM, O'Brien RL, Born W, Tigelaar RE, Allison JP. Limited diversity of T-cell receptor gamma-chain expression of murine Thy-1+ dendritic epidermal cells revealed by V gamma 3-specific monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America. 86: 4185-9. PMID 2726770 DOI: 10.1073/Pnas.86.11.4185  0.438
1989 Miller JFAP, Morahan G, Allison J. Extrathymic acquisition of tolerance by T lymphocytes. Cold Spring Harbor Symposia On Quantitative Biology. 54: 807-813. PMID 2701217 DOI: 10.1101/Sqb.1989.054.01.094  0.432
1989 Nairn RS, McIntyre BW, Richie ER, Allison JP. Characterization of env gene recombination in x-ray--induced thymomas of C57BL/6 mice. Molecular Carcinogenesis. 2: 126-30. PMID 2675902 DOI: 10.1002/Mc.2940020304  0.334
1989 Morahan G, Brennan FE, Bhathal PS, Allison J, Cox KO, Miller JFAP. Expression in transgenic mice of class I histocompatibility antigens controlled by the metallothionein promoter. Proceedings of the National Academy of Sciences of the United States of America. 86: 3782-3786. PMID 2657728 DOI: 10.1073/Pnas.86.10.3782  0.384
1989 Groghan TW, Davignon JL, Evans J, Allison JP, Eisenberg RA, Frelinger JA, Cohen PL. Diminished expression of the t cell receptor on the expanded lymphocyte population in mrl/mp-1pr/1pr mice Autoimmunity. 2: 97-111. PMID 2562377 DOI: 10.3109/08916938909019947  0.386
1989 Asarnow DM, Goodman T, LeFrancois L, Allison JP. Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells Nature. 341: 60-62. PMID 2528075 DOI: 10.1038/341060A0  0.456
1989 Kyewski BA, Schirrmacher V, Allison JP. Antibodies against the T cell receptor/CD3 complex interfere with distinct intra-thymic cell-cell interactions in vivo: correlation with arrest of T cell differentiation. European Journal of Immunology. 19: 857-63. PMID 2525475 DOI: 10.1002/Eji.1830190512  0.49
1988 Richie ER, McEntire B, Phillips J, Allison JP. Altered expression of lymphocyte differentiation antigens on phorbol ester-activated CD4+8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 140: 4115-22. PMID 3259607  0.326
1988 Richie ER, McEntire B, Crispe N, Kimura J, Lanier LL, Allison JP. Alpha/beta T-cell antigen receptor gene and protein expression occurs at early stages of thymocyte differentiation. Proceedings of the National Academy of Sciences of the United States of America. 85: 1174-8. PMID 2963339 DOI: 10.1073/Pnas.85.4.1174  0.46
1988 Allison JP, Hayran WL, Asarnow D, Tigelaar RE, Tucker PW, Bonyhadi M. γδ Antigen receptors of Thy-1 + dendritic epidermal cells: Implications for thymic differentiation Immunologic Research. 7: 292-302. PMID 2906352 DOI: 10.1007/Bf02935534  0.363
1988 Kuziel WA, Takashima A, Bonyhadi M, Bergstresser PR, Allison JP, Tigelaar RE, Tucker PW. Regulation of T-cell receptor γ-chain RNA expression in murine Thy-1+ dendritic epidermal cells Nature. 328: 263-266. PMID 2885757 DOI: 10.1038/328263A0  0.464
1988 Asarnow DM, Kuziel WA, Bonyhad M, Tigelaar RE, Tucker PW, Allison JP. Limited diversity of γδ antigen receptor genes of thy-1+ dendritic epidermal cells Cell. 55: 837-847. PMID 2847872 DOI: 10.1016/0092-8674(88)90139-0  0.464
1988 Havran WL, Allison JP. Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors. Nature. 335: 443-5. PMID 2458531 DOI: 10.1038/335443A0  0.412
1987 Allison JP, Lanier LL. The T-cell antigen receptor gamma gene: rearrangement and cell lineages. Immunology Today. 8: 293-6. PMID 25290833 DOI: 10.1016/0167-5699(87)90014-4  0.509
1987 Bonyhadi M, Weiss A, Tucker PW, Tigelaar RE, Allison JP. Delta is the Cx-gene product in the γ/δ antigen receptor of dendritic epidermal cells Nature. 330: 574-576. PMID 3500417 DOI: 10.1038/330574A0  0.392
1987 Lanier LL, Serafini AT, Ruitenberg JJ, Cwirla S, Federspiel NA, Phillips JH, Allison JP, Weiss A. The gamma T-cell antigen receptor. Journal of Clinical Immunology. 7: 429-40. PMID 3320076 DOI: 10.1007/Bf00915052  0.47
1987 Crispe IN, Shimonkevitz RP, Husmann LA, Kimura J, Allison JP. Expression of T cell antigen receptor beta-chains on subsets of mouse thymocytes. Analysis by three-color flow cytometry. Journal of Immunology (Baltimore, Md. : 1950). 139: 3585-9. PMID 2960738  0.318
1987 Havran WL, Poenie M, Kimura J, Tsien R, Weiss A, Allison JP. Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature. 330: 170-3. PMID 2959867 DOI: 10.1038/330170A0  0.418
1987 Allison JP, Lanier LL. Structure, function, and serology of the T-cell antigen receptor complex Annual Review of Immunology. 5: 503-540. PMID 2439105 DOI: 10.1146/Annurev.Iy.05.040187.002443  0.493
1987 Lanier LL, Federspiel NA, Ruitenberg JJ, Phillips JH, Allison JP, Littman D, Weiss A. The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. The Journal of Experimental Medicine. 165: 1076-94. PMID 2435832 DOI: 10.1084/Jem.165.4.1076  0.451
1987 O'Neill HC, McGrath MS, Allison JP, Weissman IL. A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus. Cell. 49: 143-51. PMID 2435413 DOI: 10.1016/0092-8674(87)90764-1  0.431
1987 Allison JP, Lanier LL. The T-cell antigen receptor gamma gene: rearrangement and cell lineages Immunology Today. 8: 293-296. DOI: 10.1016/0167-5699(87)90014-4  0.413
1986 Saunders PH, McIntyre BW, Lawlor DA, Bridges WJ, Allison JP. The congenic mutant B6.C-H-2bm-1 (H-2bm-1) serological response to the T-cell receptor on EL4. Cellular Immunology. 101: 586-92. PMID 3757049 DOI: 10.1016/0008-8749(86)90168-1  0.437
1986 Lanier LL, Allison JP, Phillips JH. Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. Journal of Immunology (Baltimore, Md. : 1950). 137: 2501-7. PMID 3531334  0.313
1986 Lanier LL, Ruitenberg JJ, Allison JP, Weiss A. Distinct epitopes on the T cell antigen receptor of HPB-ALL tumor cells identified by monoclonal antibodies. Journal of Immunology (Baltimore, Md. : 1950). 137: 2286-92. PMID 2428866  0.361
1985 Pellegrino MA, Russo C, Allison JP. HLA antigens in serum. Methods in Enzymology. 108: 614-24. PMID 6527659 DOI: 10.1016/S0076-6879(84)08122-2  0.356
1985 Allison JP, Lanier LL. Identification of antigen receptor-associated structures on murine T cells Nature. 314: 107-109. PMID 2579338 DOI: 10.1038/314107A0  0.467
1985 Allison JP, McIntyre BW, Ridge LL, Gross-Pelose J, Lanier LL. Molecular characterization of the murine T cell antigen receptor and associated structures. Federation Proceedings. 44: 2870-3. PMID 2412897  0.325
1984 McIntyre BW, Allison JP. Biosynthesis and processing of murine T-cell antigen receptor. Cell. 38: 659-65. PMID 6488315 DOI: 10.1016/0092-8674(84)90260-5  0.354
1984 Allison JP, Ridge L, Lund J, Gross-Pelose J, Lanier L, McIntyre BW. The murine T cell antigen receptor and associated structures. Immunological Reviews. 81: 145-60. PMID 6210241 DOI: 10.1111/J.1600-065X.1984.Tb01108.X  0.428
1983 Kappler J, Kubo R, Haskins K, Hannum C, Marrack P, Pigeon M, McIntyre B, Allison J, Trowbridge I. The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. Cell. 35: 295-302. PMID 6605199 DOI: 10.1016/0092-8674(83)90232-5  0.431
1983 Lanier LL, Richie ER, Howell AL, Allison JP. Expression of Ly-1 and Ly-2 on a spontaneous AKR B-cell lymphoma Immunogenetics. 17: 655-659. PMID 6602763 DOI: 10.1007/Bf00366133  0.308
1983 McIntyre BW, Allison JP. The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell. 34: 739-46. PMID 6194888 DOI: 10.1016/0092-8674(83)90530-5  0.464
1982 Allison JP, McIntyre BW, Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. Journal of Immunology (Baltimore, Md. : 1950). 129: 2293-300. PMID 6181166  0.353
1982 Kline K, Allison JP, Sanders BG. Chemical and immunological characterization of developmentally expressed chicken erythroid surface membrane antigens. Developmental Biology. 91: 389-96. PMID 6178635 DOI: 10.1016/0012-1606(82)90044-6  0.318
1979 Callahan GN, Allison JP, Pellegrino MA, Reisfeld RA. Physical association of histocompatibility antigens and tumor-associated antigens on the surface of murine lymphoma cells. Journal of Immunology (Baltimore, Md. : 1950). 122: 70-4. PMID 762424  0.508
1979 Walker LE, Allison JP, Silver J, Pellegrino MA, Reisfeld RA, Ferrone S. IS SEROLOGICAL POLYMORPHISM OF HUMAN DR ANTIGENS DETERMINED BY STRUCTURAL DIFFERENCES IN THE SMALLER (β) CHAIN Cell Biology and Immunology of Leukocyte Function. 271-276. DOI: 10.1016/B978-0-12-569650-0.50041-3  0.522
1978 Allison JP, Belvedere M, Reisfeld RA, Pellegrino MA, Ferrone S. Serologic and immunochemical characterization of HLA-A9 xenoantisera. Journal of Immunology (Baltimore, Md. : 1950). 121: 579-85. PMID 681750  0.411
1978 Allison JP, Ferrone S, Walker LE, Pellegrino MA, Silver J, Reisfeld RA. Partial amino acid sequence of HLA‐A9 antigen purified with a specific xenoantiserum Transplantation. 26: 451-453. PMID 569916  0.403
1978 Allison JP, Walker LE, Russell WA, Pellegrino MA, Ferrone S, Reisfeld RA, Frelinger JA, Silver J. Murine Ia and human DR antigens. Homology of amino-terminal sequences Proceedings of the National Academy of Sciences of the United States of America. 75: 3953-3956. PMID 99745 DOI: 10.1073/Pnas.75.8.3953  0.477
1978 Callahan GN, Allison JP. H-2 antigens on a murine lymphoma are associated with additional proteins. Nature. 271: 165-7. PMID 74802 DOI: 10.1038/271165A0  0.416
1977 Allison JP, Ferrone S, Pellegrino MA, Reisfeld RA. Procedure for the selection of HLA xenoantisera for immunochemical characterization of HLA antigens. Transplantation Proceedings. 9: 601-4. PMID 194373  0.411
1977 Allison JP, Pellegrino MA, Ferrone S, Callahan GN, Reisfeld RA. Biologic and chemical characterization of HLA antigens in human serum. Journal of Immunology (Baltimore, Md. : 1950). 118: 1004-9. PMID 191523  0.423
1977 Allison JP, Pellegrino MA, Reisfeld RA, Ferrone S. An immune adsorption technique for analysis of antigenic determinants reacting with HLA antisera. Transplantation Proceedings. 9: 1691-3. PMID 74875  0.446
1977 Ferrone S, Mittal KK, Pellegrino MA, Allison JP, Reisfeld RA. Immunogenicity of HLA antigens purified from serum. Transplantation. 23: 7-15. PMID 65035 DOI: 10.1097/00007890-197701000-00002  0.511
1976 Ferrone S, Pellegrino MA, Allison JP, Reisfeld RA. [Biological and chemical aspects of histocompatibility antigens in serum]. Haematologica. 61: 397-417. PMID 828605  0.428
1976 Reisfeld RA, Allison JP, Ferrone S, Pellegrino MA, Poulik MD. HL-A antigens in serum and urine: isolation, characterization, and immunogenic properties. Transplantation Proceedings. 8: 173-8. PMID 59439  0.416
1975 Prager MD, Ludden CM, Mandy WJ, Allison JP, Kitto GB. Endotoxin-stimulated immune response to modified lymphoma cells. Journal of the National Cancer Institute. 54: 773-5. PMID 1168264 DOI: 10.1093/Jnci/54.3.773  0.705
1975 Callahan GN, Ferrone S, Allison JP, Reisfeld RA. Detection of H-2 antigens in serum. Transplantation. 20: 431-3. PMID 174256 DOI: 10.1097/00007890-197511000-00014  0.469
1972 Allison JP, Davidson L, Gutierrez-Hartman A, Kitto GB. Insolubilization of L-asparaginase by covalent attachment to nylon tubing. Biochemical and Biophysical Research Communications. 47: 66-73. PMID 5027141 DOI: 10.1016/S0006-291X(72)80011-1  0.6
1971 Allison JP, Mandy WJ, Kitto GB. The substrate specificity of L-asparaginase from Alcaligenes eutrophus. Febs Letters. 14: 107-108. PMID 11945731 DOI: 10.1016/0014-5793(71)80112-6  0.608
Show low-probability matches.